<DOC>
	<DOCNO>NCT01359943</DOCNO>
	<brief_summary>The study compare efficacy assess safety secukinumab give 3 intravenous ( i.v . ) load dos weekly sub-cutaneous ( s.c. ) loading dos , compare placebo , follow monthly s.c. injection patient active Rheumatoid Arthritis ( RA ) despite treatment Methotrexate .</brief_summary>
	<brief_title>Efficacy , Safety Tolerability Secukinumab Patients With Rheumatoid Arthritis Taking Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : presence RA classify ACR 2010 revise criterion least 3 month screen must take MTX least 3 month randomization must currently stable dose MTX least 4 week randomization . At Baseline : Disease activity criterion define &gt; 6 tender joint 68 &gt; 6 swollen joint 66 least 1 follow screening : AntiCCP antibody positive OR Rheumatoid Factor positive least 1 follow screening : hsCRP ≥ 10 mg/L OR ESR ≥ 28 Exclusion criterion : RA patient functional status class IV accord ACR 1991 revise criterion Previous exposure secukinumab biologic drug directly target IL17 IL17 receptor Previous exposure ever antiTNFa agent immunomodulatory biologic agent ( experimental approve ) Patients take high potency opioid analgesic ( e.g. , methadone , hydromorphone , morphine ) Any therapy intraarticular injection ( e.g . corticosteroid , hyaluronan ) require treatment arthritis within 4 week randomization Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>RA</keyword>
	<keyword>secukinumab</keyword>
	<keyword>AIN457</keyword>
	<keyword>inflammatory joint</keyword>
	<keyword>American College Rheumatology</keyword>
	<keyword>ACR</keyword>
</DOC>